Fly News Breaks for August 7, 2019
Aug 7, 2019 | 07:52 EDT
Oppenheimer analyst Jay Olson lowered his price target for Sage Therapeutics to $190 from $200 after the company provided Q2 results and a business update, including ongoing Zulresso launch and an R&D portfolio prioritization process to optimize pipeline investments. The analyst reiterates an Outperform rating on the shares.
News For SAGE From the Last 2 Days
There are no results for your query SAGE